JP2013505223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505223A5 JP2013505223A5 JP2012529298A JP2012529298A JP2013505223A5 JP 2013505223 A5 JP2013505223 A5 JP 2013505223A5 JP 2012529298 A JP2012529298 A JP 2012529298A JP 2012529298 A JP2012529298 A JP 2012529298A JP 2013505223 A5 JP2013505223 A5 JP 2013505223A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- dose
- epcamxcd3 bispecific
- period
- epcamxcd3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| US61/243,651 | 2009-09-18 | ||
| EP09170715.8 | 2009-09-18 | ||
| EP09170715 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| EP10164596.8 | 2010-06-01 | ||
| EP10164596 | 2010-06-01 | ||
| US61/344,147 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505223A JP2013505223A (ja) | 2013-02-14 |
| JP2013505223A5 true JP2013505223A5 (enExample) | 2013-11-28 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529298A Pending JP2013505223A (ja) | 2009-09-18 | 2010-09-20 | ＥｐＣＡＭｘＣＤ３二重特異性抗体を投与するための投与計画 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120244161A1 (enExample) |
| EP (1) | EP2477653A1 (enExample) |
| JP (1) | JP2013505223A (enExample) |
| KR (1) | KR20120083359A (enExample) |
| CN (1) | CN102711825A (enExample) |
| AU (1) | AU2010297258A1 (enExample) |
| BR (1) | BR112012008345A2 (enExample) |
| CA (1) | CA2774732A1 (enExample) |
| IL (1) | IL218637A0 (enExample) |
| IN (1) | IN2012DN03172A (enExample) |
| MX (1) | MX2012003175A (enExample) |
| NZ (1) | NZ598601A (enExample) |
| RU (1) | RU2012115480A (enExample) |
| SG (2) | SG10201405434VA (enExample) |
| WO (1) | WO2011033105A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102293537B1 (ko) * | 2016-03-30 | 2021-08-25 | 린톤 퍼시픽 아게 | 요로의 신생물을 치료하는데 사용하기 위한 다중특이적 항체 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AR089114A1 (es) | 2011-12-09 | 2014-07-30 | Amgen Res Munich Gmbh | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| CN110845618A (zh) * | 2013-02-26 | 2020-02-28 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| ES2728668T3 (es) * | 2014-01-08 | 2019-10-28 | Univ Leland Stanford Junior | Terapia dirigida para el cáncer de pulmón de células pequeñas |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| PT3377103T (pt) * | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN109476756B (zh) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| IL273119B2 (en) | 2017-09-08 | 2023-10-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| WO2021262963A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
| CN120818062A (zh) * | 2021-11-19 | 2025-10-21 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| JP4948174B2 (ja) | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| JP5129122B2 (ja) * | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | 癌治療のための抗体およびグルココルチコイドの組み合わせ |
-
2010
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en not_active Ceased
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102293537B1 (ko) * | 2016-03-30 | 2021-08-25 | 린톤 퍼시픽 아게 | 요로의 신생물을 치료하는데 사용하기 위한 다중특이적 항체 |
| KR102435747B1 (ko) * | 2016-03-30 | 2022-08-23 | 린톤 퍼시픽 아게 | 요로의 신생물을 치료하는데 사용하기 위한 다중특이적 항체 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505223A5 (enExample) | ||
| RU2012115480A (ru) | РЕЖИМ ДОЗИРОВАНИЯ ПРИ ВВЕДЕНИИ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА EpCAMxCD3 | |
| ES2909910T3 (es) | Tratamiento contra el cáncer usando combinaciones de inhibidores de ERK y RAF | |
| CN108392633B (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP7520366B2 (ja) | 腫瘍療法の副作用の予防または治療方法 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021063120A5 (enExample) | ||
| JP2018523686A5 (enExample) | ||
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| CA2978431C (en) | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| JP2013518912A5 (enExample) | ||
| JP2013508392A5 (enExample) | ||
| Chen et al. | Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| JP2006265245A5 (enExample) | ||
| EP4212160A1 (en) | Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy | |
| JP2014500278A5 (enExample) | ||
| US10583111B2 (en) | Method for preventing or treating diseases associated with the inhibition of EGFR | |
| WO2006004917A3 (en) | Method of treating breast cancer using a combination of 1alpha, 24-dihydroxyvitamin d2 and a further chemotherapeutic agent | |
| JP2014523398A5 (enExample) | ||
| JP7156949B2 (ja) | 逐次的抗癌治療 | |
| Xu et al. | Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study | |
| MX2025009402A (es) | Anticuerpos, fragmentos de union al antigeno y metodos de uso |